Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Cash Flows

v3.20.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
3 Months Ended
Mar. 28, 2020
Mar. 30, 2019
Cash flows from operating activities:    
Net (loss) income $ (17,223) $ 16,404
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation and amortization 8,376 8,571
Loss on disposal of assets 24 71
Goodwill impairment 31,871  
Stock-based compensation expense 1,533 1,368
Amortization of debt issuance costs 179 179
Benefit for deferred income taxes (1,186) (322)
Change in fair value of contingent consideration   719
Forward contract (gains) losses, net (440) 24
Other, net 136 549
(Increase) decrease in:    
Accounts receivable (6,838) (8,848)
Inventories (2,818) (3,729)
Income taxes receivable 1,415  
Other current assets (2,740) (2,455)
Other assets 1,213 1,088
Increase (decrease) in:    
Accounts payable 3,867 662
Accrued expenses and other liabilities (4,652) 3,496
Income taxes payable 3,051 2,710
Other noncurrent liabilities (701) (659)
Net cash provided by operating activities 15,067 19,828
Cash flows from investing activities:    
Capital expenditures (2,937) (8,792)
Proceeds from dispositions of equipment 3 64
Cash settlement of forward contracts 1,634  
Net cash used in investing activities (1,300) (8,728)
Cash flows from financing activities:    
Borrowings on revolving credit facility 2,000 35,282
Repayment of borrowings on revolving credit facility (5,500) (48,000)
Repayment of borrowings on long-term non-revolving debt (2,100) (1,623)
Proceeds from stock issued 355 408
Dividends to shareholders (2,885) (2,878)
Other financing activities (815) (881)
Net cash used in financing activities (8,945) (17,692)
Effect of exchange rate changes on cash, cash equivalents and restricted cash 310 (167)
Net increase (decrease) in cash, cash equivalents and restricted cash 5,132 (6,759)
Cash, cash equivalents and restricted cash, beginning of period 22,162 23,515
Cash, cash equivalents and restricted cash, end of period $ 27,294 $ 16,756